In this article, we will look at the 11 Best 52-Week Low Stocks to Buy Right Now.

On July 2, Tom Lee, Fundstrat’s Head of Research and CIO, joined CNBC Television to discuss market conditions. He noted that the investors remain skeptical despite strong market gains. He elaborated that he used the term skeptical because the market is starting the month of July with the S&P 500 up 5% year-to-date. However, the investors are still not ready to own the stock market. This is because of the skepticism that perhaps President Trump is not going to extend the tariff exemptions in July.

Lee believes that despite a lot of favorable seasonals, the investors are not yet ready to invest with full confidence. This has led to one of the most hated V-shaped rallies in years. Lee notes that there is still around $7 trillion of cash on the sidelines. He also pointed out sectors to buy for the second half, which include small caps, financials, large and regional banks, industrials, Mag Seven, and some washed-out stocks.

With that, let’s take a look at the 11 Best 52-Week Low Stocks to Buy Right Now.

Our Methodology 

To curate the list of 11 Best 52-Week Low Stocks to Buy Right Now., we used the Finviz Stock Screener, Yahoo Finance, and CNN. Using the screener, we aggregated a list of stocks trading within 0%-3% of their 52-week lows, but analysts see more than 15% upside. Next, we cross-checked the 52-week range for each stock from Yahoo Finance and analyst upside potential from CNN and ranked the stocks in ascending order of the upside potential. We have also added the number of hedge funds holding each stock, sourced from the Insider Monkey Q1 2025 database. Please note that the data was recorded on June 30, 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

11 Best 52-Week Low Stocks to Buy Right Now

11. Motorola Solutions, Inc. (NYSE:MSI)

Price: $418.66

52 Week Range: $384.51 – $507.82 

Analyst Upside: 22.06%

Number of Hedge Fund Holders: 51

Motorola Solutions, Inc. (NYSE:MSI) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On July 9, Motorola Solutions, Inc. (NYSE:MSI) announced the launch of its WAVE PTX communication platform in Peru.

The platform is a subscription-based push-to-talk solution that lets workers communicate securely using voice and data.

The service is designed to help companies connect to their teams instantly, no matter where they are. It works across 3G, LTE, WiFi, and traditional radio networks. Using the service teams can send images, videos, documents, and messages. It works with devices that people already use such as smartphones, tablets, and radios.

One of the key features of WAVE PTX is the mapping tool that allows real-time tracking of workers and resources, helping companies to track workers during emergency situations. The devices are now available in Peru through authorized distributors.

Motorola Solutions, Inc. (NYSE:MSI) is a technology company that provides advanced safety and security solutions for agencies and organizations.

10. Alcon Inc. (NYSE:ALC)

Price: $87.81 

52 Week Range: $80.48 – $101.10 

Analyst Upside: 23.34% 

Number of Hedge Fund Holders: 40

Alcon Inc. (NYSE:ALC) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Alcon Inc. (NYSE:ALC) announced the approval of the Clareon PanOptix Pro intraocular lens for patients in Canada.

PanOptix Pro uses proprietary ENLIGHTEN NXT Optical technology to deliver the lowest light scatter and highest light utilization reported for any trifocal intraocular lens. The lens has achieved a record 94% light utilization, which is significant against the theoretical maximum of 96% for diffractive optics.

Moreover, the technology used in making these lenses also improves light distribution, while increasing the optical image contrast between distance and intermediate vision by 16%. The PanOptix Pro is expected to be available in Canada from Alcon Inc. (NYSE:ALC) in the single-use Clareon AutonoMe preloaded delivery system by early 2026.

Alcon Inc. (NYSE:ALC) is a leading eye care company that specializes in developing a range of eye care products. The company operates through two main business segments, including the Surgical Business and Vision Care Business.

9. ONEOK, Inc. (NYSE:OKE)

Price: $81.25 

52 Week Range: $75.47 – $118.07 

Analyst Upside: 24.31% 

Number of Hedge Fund Holders: 42

ONEOK, Inc. (NYSE:OKE) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 13, Barclays analyst Theresa Chen maintained a Hold rating on ONEOK, Inc. (NYSE:OKE) with a price target of $91. The rating reflects a conservative outlook for the company after it missed EPS estimates for the fiscal first quarter of 2025.

In the fiscal first quarter of 2025, the company posted a Net income of $691 million, reflecting significant growth from last year’s net income of $639 million. However, the net income attributable to shareholders came in at $636 million, down from $639 million a year ago. This resulted in an EPS of $1.04 and missed the market consensus by $0.20. Management noted that the earnings were offset by the absence of earnings from Interstate pipeline assets, which were sold at the end of 2024.

On the bright side, ONEOK, Inc. (NYSE:OKE) delivered increased year-over-year volumes of natural gas liquids and natural gas processing, especially in the Rocky Mountain region. The Rocky Mountain region NGL raw feed throughput volumes increased 15% year-over-year, whereas the natural gas volumes processed increased 7% during the same time. Management has reaffirmed its full-year guidance for 2025.

ONEOK, Inc. (NYSE:OKE) is a midstream energy company that specializes in the transportation, processing, and storage of natural gas and related products.

8. Merck & Co., Inc. (NYSE:MRK)

Price: $79.10 

52 Week Range: $73.31 – $129.93

Analyst Upside: 25.79% 

Number of Hedge Fund Holders: 93

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has approved ENFLONSIA for preventing respiratory syncytial virus in infants younger than 8 months. The recommendation is provisional and is pending the final approval of the CDC Director or the Health and Human Services Secretary.

Merck & Co., Inc. (NYSE:MRK) noted that ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, simplifying dosing logistics. Moreover, earlier this month, the FDA approved ENFLONSIA based on the strong clinical trial data from the Phase 2b/3 CLEVER and Phase 3 SMART trials. The results showed a 60.5% reduction in medically attended RSV lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that operates through two main business segments including the Pharmaceuticals and Animal Health Segments. It is known for Keytruda and Gardasil, which are the main sources of the company’s revenue.

7. Elevance Health, Inc. (NYSE:ELV)

Price: $381.49 

52 Week Range: $357.45 – $567.26 

Analyst Upside: 27.00% 

Number of Hedge Fund Holders: 75

Elevance Health, Inc. (NYSE:ELV) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 18,  Wells Fargo analyst Stephen Baxter maintained a Buy rating on Elevance Health, Inc. (NYSE:ELV) with a price target of $478. The bullish sentiment came after the company exceeded analyst expectations in the fiscal first quarter of 2025, despite industry challenges.

Elevance Health, Inc. (NYSE:ELV) delivered an operating revenue of $48.8 billion, up 15.4% from Q1 2024, and ahead of expectations by $2.52 billion. The EPS of $11.97 also topped the analyst target by $0.49. This was driven by an increased number of Medical Members, which grew to 45.8 million, up 90,000 since year-end. Management attributed this growth to targeted expansion and strong retention in Medicare Advantage.

In addition, the Individual ACA membership grew about 11% sequentially, but a slowdown is expected in Q2 as some renewals are below expectations. Elevance Health, Inc. (NYSE:ELV) was expecting the first half earnings to account for between 62% to 63% of the full year results. However, due to the slowdown in Individual ACA memberships, it now expects the first half to account for only 60%.

Elevance Health, Inc. (NYSE:ELV) is a health company in the United States, known as a major health insurer. The company aims to improve the health of individuals and communities through an integrated, whole-health approach that addresses physical, behavioral, and social needs.

6. Diageo plc (NYSE:DEO)

Price: $100.44 

52 Week Range: $99.26 – $142.73 

Analyst Upside: 34.00%

Number of Hedge Fund Holders: 39

Diageo plc (NYSE:DEO) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On July 1st, Diageo plc (NYSE:DEO) announced the completion of its sale of shareholding in Seychelles Breweries Limited to Phoenix Beverages Limited.

Diageo plc (NYSE:DEO) completed the sale of its 54.4% shareholding in Seychelles Breweries Limited to Phoenix Beverages Limited, which is a subsidiary of Mauritius-based IBL Group, for approximately $80 million. The transaction was announced on April 2, 2025. The deal reflects the company’s strategic move to focus on its portfolio management and high-margin brands while maintaining a strong presence in the Indian Ocean region through licensing agreements.

Under the terms of the deal, although Diageo plc (NYSE:DEO) has sold its majority stake, it retains ownership of its key brands produced by Seychelles Breweries, such as Guinness and Smirnoff RTDs. These brands will continue to be produced and distributed in Seychelles under new long-term license and royalty agreements with Seychelles Breweries, ensuring ongoing collaboration.

Diageo plc (NYSE:DEO) is a UK-based producer and distributor of premium alcoholic beverages. The company operates a vast portfolio of brands and has a presence in 180 countries.

5. Copart, Inc. (NASDAQ:CPRT)

Price: $48.18 

52 Week Range: $47.33 – $64.38 

Analyst Upside: 34.91% 

Number of Hedge Fund Holders: 57

Copart, Inc. (NASDAQ:CPRT) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. The company released its fiscal third quarter 2025 results on May 22, following which, JPMorgan lowered the firm’s price target on Copart, Inc. (NASDAQ:CPRT) from $60 to $55, while keeping a Neutral rating on the stock.

Copart, Inc. (NASDAQ:CPRT) delivered revenue of $1.21 billion, reflecting a 7.49% increase year-over-year. Despite the growth, revenue missed expectations by $17.1 million. On the bright side, the EPS of $0.42 came in line with the market expectations. Management noted that while the Global Unit Sales improved 1%, the US segment sales remained flat year-over-year. JPMorgan noted the company faced challenges and missed expectations due to market softness.

Qualivian Investment Partners also mentioned Copart, Inc. (NASDAQ:CPRT) in its Q1 2025 investor letter, noting the company to be a key player in the online auctions sector. The fund noted the online auctions sector to be a two-player oligopoly, where Copart, Inc. (NASDAQ:CPRT) is the larger and better-managed player.

Copart, Inc. (NASDAQ:CPRT) is a leading player in the online vehicle auctions and vehicle remarketing services. It provides a platform that enables vehicle sellers to sell vehicles over the internet using its proprietary Virtual Bidding Third Generation (VB3) auction technology.

4. Schlumberger Limited (NYSE:SLB)

Price: $34.01 

52 Week Range: $31.11 – $50.94 

Analyst Upside: 35.25%

Number of Hedge Fund Holders: 68

Schlumberger Limited (NYSE:SLB) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Arun Jayaram from J.P. Morgan reiterated a Buy rating on Schlumberger Limited (NYSE:SLB) with a price target of $44.

Analyst Arun Jayaram noted that the company has faced challenges in well construction in regions such as Saudi Arabia, North America, and Mexico, but is expected to maintain flat year-over-year revenue and margins for 2025, indicating operational stability. Moreover, Schlumberger Limited (NYSE:SLB) is also expanding into digital and low-carbon solutions, which are anticipated to drive growth in non-oil and gas sectors, enhancing its long-term prospects.

Jayaram believes that the company is well-positioned to benefit from increased spending by national oil companies, especially in the Middle East and North Africa (MENA) region. He noted that Schlumberger Limited (NYSE:SLB) is expected to generate around $4 billion in free cash flow in 2025, enabling it to return significant value to shareholders through dividends and share buybacks.

Schlumberger Limited (NYSE:SLB) is an international technology company operating in the oil and gas industry. It functions through four main segments, including Digital & Integration, Reservoir Performance, Well Construction, and Production Systems.

3. Thermo Fisher Scientific Inc. (NYSE:TMO)

Price: $408.28 

52 Week Range: $385.46 – $627.88 

Analyst Upside: 35.94%

Number of Hedge Fund Holders: 101

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO) with a price target of $570.

Analyst Brandon Couillard noted the recent Amendment to the acquisition deal with Solventum Corp (NYSE:SOLV). The revised agreement excludes Solventum’s lower-margin Drinking Water Filtration business from the acquisition, reducing the purchase price from about $4.1 billion to $4.0 billion. Couillard believes that this simplifies the transaction and also potentially accelerates its closing by the end of 2025, while improving the financial attractiveness of the deal.

The deal revision is expected to be accretive to Thermo Fisher Scientific Inc.’s (NYSE:TMO) earnings per share even after accounting for financing costs. The exclusion of the non-core Drinking Water business aligns with the focus of the company on higher-margin, higher-growth segments, supporting stronger earnings growth.

In addition, Thermo Fisher Scientific Inc. (NYSE:TMO) has demonstrated consistent quarter-over-quarter improvement in core growth, with expectations of about 5% core growth in 2025. Moreover, its long-range plan aims to achieve robust organic growth of 7% to 9%, significant operational margin expansion, and double-digit growth in operating profits.

Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading company in the life sciences and diagnostics industry.

2. Sanofi (NASDAQ:SNY)

Price: $47.85

52 Week Range: $45.80 – $60.12  

Analyst Upside: 38.88% 

Number of Hedge Fund Holders: 27

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that its Riliprubart has been granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy.

Riliprubart is a monoclonal antibody that specifically inhibits activated C1s in the classical complement pathway. The treatment is designed to block a very specific part of the immune system’s response. Orphan drug designation is a special status granted by regulatory bodies for medicines that target rare diseases or conditions where there is a high unmet medical need.

This is a significant achievement for Sanofi (NASDAQ:SNY) because, despite existing treatments, around 30% of patients do not respond adequately, leaving a significant unmet medical need. Sanofi (NASDAQ:SNY) presented 76-week long-term data from a phase 2 clinical trial at the Peripheral Nerve Society meeting in Edinburgh. The results suggest sustained efficacy and safety of Riliprubart in a broad range of CIDP patients. Management noted that two phase 3 studies are underway to further evaluate the treatment.

1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Price: $521.00 

52 Week Range: $476.49 – $1,211.20 

Analyst Upside: 43.95%

Number of Hedge Fund Holders: 66

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that its Dupixent has been approved as the only targeted medicine to treat Bullous Pemphigoid in the United States.

Bullous pemphigoid is a chronic disease characterized by intense itching, painful blisters, skin lesions, and redness. Until now, treatment options for Bullous pemphigoid were limited and often involved suppressing the immune system with oral corticosteroids, which can add to the disease burden, especially in elderly patients.

Dupixent is the first and only targeted medicine approved in the United States addressing two central drivers of type 2 inflammation. The treatment reduces itch, improves disease symptoms, and helps some patients achieve sustained remission while decreasing the need for oral corticosteroids.

The approval for Regeneron Pharmaceuticals, Inc.’s  (NASDAQ:REGN) Dupixent was based on results from the pivotal ADEPT Phase 2/3 clinical trial, which showed 18.3% of Dupixent-treated patients achieved sustained disease remission. Moreover, the regulatory submissions for Dupixent in BP are also under review in other regions, including the EU, Japan, and China.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.